x
Filter:
Filters applied
- Coronavirus (COVID-19) Collection
- HIVRemove HIV filter
- DNARemove DNA filter
- 2017 - 2022Remove 2017 - 2022 filter
Keyword
- AMR1
- BAC1
- Bacteria1
- Benzalkonium chloride1
- COVID-191
- Deoxyribonucleic Acid1
- Directly Observed Treatment Strategy1
- Disinfectants1
- DOTs1
- Human Immunodeficiency Virus1
- NDM11
- New Delhi Metallo-β-lactamase 11
- non-pharmaceuticals1
- pharmaceuticals1
- SARS-COV21
- Severe Acute Respiratory Syndrome Coronavirus 21
- TB1
- TLS1
- Translesion Synthesis Polymerase1
- Tuberculosis1
- WHO1
- World Health Organization1
Coronavirus (COVID-19) Collection
1 Results
- PerspectiveOpen Access
Antimicrobial resistance: A challenge awaiting the post-COVID-19 era
International Journal of Infectious DiseasesVol. 111p322–325Published online: September 8, 2021- Tekle Airgecho Lobie
- Aklilu Abrham Roba
- James Alexander Booth
- Knut Ivan Kristiansen
- Abraham Aseffa
- Kirsten Skarstad
- and others
Cited in Scopus: 14Antimicrobial resistance (AMR) is a global public health concern (Prestinaci, Pezzotti, & Pantosti, 2015). The main drivers of AMR include excess microbial exposure to antibiotic agents, mainly due to their overuse in agriculture and health facilities (Capozzi et al., 2013; Levy, 1998). On the other hand, progress in developing new antibiotics has remained stagnant due to scientific challenges, clinical hurdles, and low economic returns (Payne, Miller, Findlay, Anderson, & Marks, 2015). In addition to well-established factors that influence AMR, the overuse and misuse of existing antimicrobial agents have contributed to accelerating the spread of AMR during and beyond the COVID-19 pandemic (Fig. 1).